Internal Medicine · 2016 · 17 citations · 12 references
MedicineEndocrinologyPharmacologyDiabetologyGastroenterologyGastrointestinal PharmacotherapyDiabetes ManagementDiabetes MellitusDiabetic KetoacidosisIntestinal IschemiaMesenteric IschemiaSodium-glucose Cotransporter 2 InhibitorsDiabetes-related ComplicationsExploratory Abdominal SurgeryGlucose Transporter 2Lactate AcidosisLactic AcidosisNonocclusive Mesenteric IschemiaSodium-glucose CotransportSodium-glucose Cotransporter 2 Inhibition
We herein describe a patient with non-occlusive mesenteric ischemia (NOMI) potentially associated with the administration of a sodium glucose co-transporter 2 (SGLT2) inhibitor. A 60-year-old man with type 1 diabetes was transferred to our hospital due to vomiting and respiratory distress. He was treated with insulin, metformin and a SGLT2 inhibitor, which had recently been added. He was diagnosed with intestinal ischemia complicated by diabetic ketoacidosis and lactic acidosis. Urgent exploratory surgery was performed, and the gangrenous bowel was resected. Histological findings confirmed the diagnosis of NOMI. The administration of SGLT2 inhibitors therefore requires certain exceptions for type 1 diabetes and cautious monitoring for the occurrence of these possible adverse effects.
12
Infarction of the Bowel in Cardiac Failure
Norman Ende · New England Journal of Medicine · 1958 · 270 citations
Medicine, Cardiology, Pathology +17
Metformin-associated lactic acidosis in an intensive care unit
N. Peters, Nicolas Jay, Damien Barraud et al. · Critical Care · 2008 · 161 citations · Full text
Serum Enzyme Levels During Intestinal Ischemia
Jon S. Thompson, Larry E. Bragg, William W. West · Annals of Surgery · 1990 · 105 citations